

## Study: ENGOT-en24 / DESTINY-EC01

An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer

### MaNGO Sites

Prov.	City	Site	Principal Investigator	Active **
BS	Brescia	Spedali Civili	Rossella Franzini	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
LC	Lecco	Ospedale Manzoni	Antonio Ardizzoia	
MB	Monza	Ospedale San Gerardo	Stefania Canova	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
MI	Milano	Ospedale di Niguarda	Giulia Carlo Stella	
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca	
RM	Reggio Emilia	Arcispedale S. Maria N.	Alessandra Bologna	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero *	
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	

\* MaNGO Principal Investigator

\*\* MaNGO sites list to be confirmed by Sponsor